ArticleJournal of family medicine and primary care2025
Assessing the relationship between blood transfusion products and non-Hodgkin's lymphoma incidence: A longitudinal retrospective cohort study (2004-2022).
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The association between blood product transfusion and developing non-Hodgkin's lymphoma (NHL) risks remains debated. Previous studies have established a link between blood products and NHL risks among hospitalized patients. Therefore, this study aimed to evaluate the association between NHL risk and blood transfusion among recipients through a large cohort study with an 18-year follow-up. Methods: This retrospective cohort study included approximately 8,558 patients who received at least one blood transfusion from our institution's medical records between 2004 and 2022. We extracted each blood transfusion record from the system database, excluding incomplete, cancelled, and discontinued cases. Patients with lymphoma from the hospital databases were followed up until the end of 2023. Those with a prior diagnosis of NHL or any other hematologic malignancy were excluded. Histopathological analysis of biopsy specimens confirmed the NHL diagnosis. Results: In this cohort study, we analyzed participants with a median age of 46, comprising 48.2% males and 51.8% females. The administered transfusion products included packed red blood cells (pRBCs), platelets, fresh frozen plasma (FFP), and cryoprecipitate. Notably, 2 out of 8,558 (0.023%) blood recipients developed NHL, compared to 6 out of 100,000 (0.006%) in the general Saudi population, indicating a significant association between NHL risk and blood transfusion ( Conclusion: This study revealed that blood transfusion recipients had a significantly higher incidence of NHL than the general population. However, no distinct association was found between the risk of developing NHL and any specific blood transfusion product. The findings suggest that the underlying diseases necessitating blood transfusion, rather than the transfusion products themselves, may be the primary cause of the increased risk. Further research is warranted, utilizing larger samples and prospective study designs and controlling for confounding factors to elucidate the underlying reasons for this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.